Virus-like particles (VLPs) are virus-derived structures made up of one or more different
molecules with the ability to self-assemble, mimicking the form and size of a virus particle but …

Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …

Virus-like particles (VLPs) are multiprotein structures that mimic the organization and
conformation of authentic native viruses but lack the viral genome, potentially yielding safer …

Virus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory
properties of natural viruses while omitting the infectious trait. VLPs that assemble from a …

Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid
proteins from many viruses. In many cases such VLPs have structural characteristics and …

Viral infectious diseases threaten human health and global stability. Several vaccine
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …

Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These
innovative biopharmaceuticals present the remarkable advantages of closely mimicking the …

Current vaccines that provide protection against infectious diseases have primarily relied on
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …

Nowadays, viruses are not only seen as causative agents of viral infectious diseases but
also as valuable research materials for various biomedical purposes, including recombinant …

The baculovirus‐insect cell expression system is widely used in producing recombinant
proteins. This review is focused on the use of this expression system in developing …